LOGIN  |  REGISTER
Cue Biopharma
Cue Biopharma

Varex Imaging to Present at CJS Securities 24th Annual New Ideas for the New Year Virtual Conference

December 29, 2023 | Last Trade: US$7.32 0.16 2.23

SALT LAKE CITY / Dec 29, 2023 / Business Wire / Varex Imaging Corporation (Nasdaq: VREX) announced today that management is scheduled to present at CJS Securities 24th Annual New Ideas for the New Year Virtual Conference.

Management will be presenting on Wednesday, January 10, 2024 at 3:05pm EST. Further details of the conference can be found on Varex’s website at www.vareximaging.com/news.

About Varex

Varex Imaging Corporation is a leading innovator, designer and manufacturer of X-ray imaging components, which include X-ray tubes, digital detectors and other image processing solutions that are key components of X-ray imaging systems. With a 70+ year history of successful innovation, Varex’s products are used in medical imaging as well as in industrial and security imaging applications. Global OEM manufacturers incorporate Varex’s X-ray sources, digital detectors, connecting devices and imaging software in their systems to detect, diagnose, protect and inspect. Headquartered in Salt Lake City, Utah, Varex employs approximately 2,400 people located in North America, Europe, and Asia. For more information visit vareximaging.com.

Viking Therapeutics

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page